BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ungar B, Glidai Y, Yavzori M, Picard O, Fudim E, Lahad A, Haberman Y, Shouval DS, Weintraub I, Eliakim R, Ben-horin S, Weiss B. Association Between Infliximab Drug and Antibody Levels and Therapy Outcome in Pediatric Inflammatory Bowel Diseases. Journal of Pediatric Gastroenterology & Nutrition 2018;67:507-12. [DOI: 10.1097/mpg.0000000000002051] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
Number Citing Articles
1 Hu W, Feng Y, Ye Z, Tang Z, Qian L, Wang Y, Huang Y. The Association Between Genetic Variants, Pharmacokinetics, and Infliximab Efficacy in Pediatric Patients With Crohn's Disease in China. Front Pediatr 2021;9:744599. [PMID: 34966700 DOI: 10.3389/fped.2021.744599] [Reference Citation Analysis]
2 Conrad MA, Kelsen JR. The Treatment of Pediatric Inflammatory Bowel Disease with Biologic Therapies. Curr Gastroenterol Rep 2020;22:36. [PMID: 32542562 DOI: 10.1007/s11894-020-00773-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
3 Jongsma MME, Winter DA, Huynh HQ, Norsa L, Hussey S, Kolho KL, Bronsky J, Assa A, Cohen S, Lev-Tzion R, Van Biervliet S, Rizopoulos D, de Meij TGJ, Shouval DS, Wine E, Wolters VM, Martinez-Vinson C, de Ridder L; Paediatric IBD Porto Group of ESPGHAN. Infliximab in young paediatric IBD patients: it is all about the dosing. Eur J Pediatr 2020;179:1935-44. [PMID: 32813123 DOI: 10.1007/s00431-020-03750-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
4 Kolho KL. Therapeutic Drug Monitoring and Outcome of Infliximab Therapy in Pediatric Onset Inflammatory Bowel Disease. Front Pediatr 2020;8:623689. [PMID: 33520903 DOI: 10.3389/fped.2020.623689] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Moore H, Dolce P, Devas N, Baldassano R, Martinelli M. Post-induction infliximab trough levels and disease activity in the clinical evolution of pediatric ulcerative colitis. United European Gastroenterol J 2020;8:425-35. [PMID: 32213038 DOI: 10.1177/2050640620912877] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
6 Papamichael K, Cheifetz AS. Therapeutic drug monitoring in patients on biologics: lessons from gastroenterology. Curr Opin Rheumatol 2020;32:371-9. [PMID: 32412995 DOI: 10.1097/BOR.0000000000000713] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 5.0] [Reference Citation Analysis]
7 Clarkston K, Tsai YT, Jackson K, Rosen MJ, Denson LA, Minar P. Development of Infliximab Target Concentrations During Induction in Pediatric Crohn Disease Patients. J Pediatr Gastroenterol Nutr 2019;69:68-74. [PMID: 31232885 DOI: 10.1097/MPG.0000000000002304] [Cited by in Crossref: 19] [Cited by in F6Publishing: 10] [Article Influence: 9.5] [Reference Citation Analysis]
8 Papamichael K, Cheifetz AS, Melmed GY, Irving PM, Vande Casteele N, Kozuch PL, Raffals LE, Baidoo L, Bressler B, Devlin SM, Jones J, Kaplan GG, Sparrow MP, Velayos FS, Ullman T, Siegel CA. Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol 2019;17:1655-1668.e3. [PMID: 30928454 DOI: 10.1016/j.cgh.2019.03.037] [Cited by in Crossref: 87] [Cited by in F6Publishing: 65] [Article Influence: 29.0] [Reference Citation Analysis]
9 Grossberg LB, Cheifetz AS, Papamichael K. Therapeutic Drug Monitoring of Biologics in Crohn’s Disease. Gastroenterology Clinics of North America 2022. [DOI: 10.1016/j.gtc.2021.12.007] [Reference Citation Analysis]